• United-Guardian posted Q1 2026 net income of USD 818,902, up 46% year over year; EPS rose to USD 0.18.
• Net sales climbed 16% to USD 2.87 million, led by pharmaceutical product sales up 24% and cosmetic ingredient sales up 21%.
• Operating income increased 5.16% to USD 642,449, while settlement income totaled USD 303,133.
• Renacidin drove the pharmaceutical gain; efforts shift to boosting healthcare practitioner awareness, with international market entry under review.
• Cosmetic demand improved as Ashland Specialty Ingredients’ purchases rose 45%; first order received for Natrajel, with two new ingredients targeted for late 2026/early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United-Guardian Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.